Question explored with the scientific record
Effective treatment for polymyalgia rheumatica that is not prednisone
The honest answer: no drug has been proven to replace prednisone in PMR, but two steroid-sparing options have real trial support.
The strongest evidence is for methotrexate. A randomized, double-blind, placebo-controlled trial of 72 newly diagnosed patients found that adding methotrexate to prednisone roughly doubled the chance of being steroid-free at 76 weeks (28 of 32 vs 16 of 30) and cut flare-ups nearly in half [2]. A separate Australian audit of 70 patients also linked methotrexate to lower inflammation and reduced steroid exposure, though it lacked a control group [1]. The catch: methotrexate caused side effects in about a quarter of users in that audit, including nausea, hair loss, and one case of lung inflammation [1].
For people who cannot tolerate steroids at all, tocilizumab (an IL-6 blocker) is the next option. One case report showed a woman who failed methotrexate and etanercept reached sustained remission on tocilizumab alone [3]. A 10-patient retrospective study found it cut average prednisone doses from about 21 mg to 4 mg daily, but one patient died of a heart attack with persistent vasculitis found at autopsy [4]. A 2026 review now recommends IL-6 blockers for high-risk patients, citing randomized trials [5].
Vitamin D is the only non-drug adjunct with data. A 2025 study of 29 PMR patients found that those whose vitamin D rose substantially after three months of supplementation were more likely to reach early remission, though baseline levels predicted nothing [6].
| Treatment | Evidence strength | Steroid-sparing effect | Key risk |
|---|---|---|---|
| Methotrexate | Randomized trial [2] | Doubled steroid-free rate at 76 weeks | GI upset, lung inflammation [1] |
| Tocilizumab | Case reports, retrospective [3][4] | Cut prednisone ~5-fold | Serious infection, death in 1/10 [4] |
| Vitamin D | Small retrospective [6] | Possible remission aid | Minimal |
The evidence base is thin and mostly observational. No trial has compared these drugs head-to-head, and long-term safety data is limited. The 2004 methotrexate trial is the only randomized controlled evidence, and it still used prednisone in both arms [2].
My call: methotrexate is the best-supported steroid-sparing option, worth trying early in most patients; tocilizumab is a reasonable second-line for those who fail or cannot take steroids. Confidence: moderate.
Sources used 6
-
Efficacy of methotrexate in polymyalgia rheumatica in routine rheumatology clinical care
In a retrospective audit at two Australian tertiary rheumatology centres, methotrexate co-prescription in polymyalgia rheumatica was associated with reduced inflammatory markers and lowered glucocorticoid exposure, though the study lacked a control group.
DOI: 10.1111/imj.14779 -
Prednisone plus Methotrexate for Polymyalgia Rheumatica
A multicenter randomized, double-blind, placebo-controlled trial showing that adding methotrexate to prednisone in newly diagnosed polymyalgia rheumatica increases the proportion of patients who are steroid-free at 76 weeks and reduces cumulative prednisone exposure, with compar…
DOI: 10.7326/0003-4819-141-7-200410050-00005 -
Effective Control of Polymyalgia Rheumatica With Tocilizumab
This is a case report of a 62-year-old woman with polymyalgia rheumatica who achieved sustained remission on tocilizumab after intolerance to glucocorticoids and failure of methotrexate and etanercept, suggesting IL-6 receptor blockade as a promising PMR therapy that warrants fu…
DOI: 10.1097/RHU.0b013e3182a6aa0e -
Tocilizumab for the treatment of large‐vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica
A retrospective study of 10 patients with relapsing/refractory giant cell arteritis, Takayasu arteritis, or polymyalgia rheumatica treated with tocilizumab (IL-6 receptor blockade) showing rapid clinical and serologic improvement and substantial glucocorticoid-sparing, but with …
DOI: 10.1002/acr.21750 -
Polymyalgia rheumatica
This CME review synthesizes current diagnosis and management of polymyalgia rheumatica, highlighting early rheumatologic referral, glucocorticoid-sparing IL-6 receptor inhibition, the PMR–giant cell arteritis spectrum, and emerging therapies such as secukinumab.
DOI: 10.1007/s00393-026-01859-5 -
Vitamin D Status and Response to Supplementation as Predictive Factors for Early Remission in Polymyalgia Rheumatica: A Retrospective Longitudinal Investigation
A retrospective longitudinal study of polymyalgia rheumatica (PMR) patients and matched elderly controls found that while baseline 25-hydroxyvitamin D [25(OH)D] levels do not differ from controls nor predict long-term outcomes, the magnitude of 25(OH)D rise after three months of…
DOI: 10.3390/nu17172839